ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 11:45 AM

ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceuticals $ACHN Hit a high of 13.38 Currently 11:15 Last price 12.85 unch unch With a day low of 12.22 and a current volume of 7,590,134.

ACHN Achillion Pharmaceuticals Recent Headline News

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 32 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 42 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 1 hr 37 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 7 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - 2 hrs 14 mins ago
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 15.84 (+0.98), AMD: 2.73 (-0.03), ACHN: 12.73 (-0.12), CLDX: 14.72 (-0.09), ILMN: 187.87 (-0.40)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 2 hrs 39 mins ago

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.09 (-0.31), ACHN: 12.73 (-0.12), ILMN: 187.87 (-0.40), AFFX: 9.41 (-0.01)

Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.73 (-0.12), DNDN: 0.18 (unch), CMCSK: 51.83 (-1.00), ARCP: 8.63 (+0.13), MSFT: 48.86 (-0.03), INTC: 33.44 (+0.18), CMCSA: 52.00 (-0.95), AAPL: 108.85 (+0.02), CSCO: 25.19 (+0.04)

Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.08 (-0.05), PCMI: 8.60 (-0.20), ACHN: 12.73 (-0.12), TGTX: 13.00 (+0.45), AGIO: 84.61 (+2.83), LIOX: 5.31 (-0.23), PLNR: 7.14 (-0.54)

Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.70 (-0.19), JRJC: 7.74 (+1.30), NAVB: 1.00 (-0.03), SANW: 3.60 (-0.04), PLPM: 1.70 (+0.03), RYN: 26.68 (-2.14), INFU: 2.85 (-0.12), LIOX: 5.31 (-0.23), DY: 27.66 (-0.31), MTZ: 24.21 (-0.72), CGIX: 6.49 (-0.19), MUX: 1.32 (+0.09), OREX: 5.08 (-0.05), URRE: 2.43 (-0.13), ACHN: 12.73 (-0.12), REN: 2.60 (-0.30), MPO: 3.14 (-0.07), AKBA: 9.71 (+0.72), TRX: 1.09 (+0.05), PLNR: 7.14 (-0.54)

Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST

ACHN: 12.73 (-0.12)

Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31)

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST

PT: 1.76 (+0.12), GPRO: 75.40 (-0.35), OREX: 5.08 (-0.05), GOGO: 17.81 (-0.59), JRJC: 7.74 (+1.30), UEC: 1.84 (-0.06), ACHN: 12.73 (-0.12), ARQL: 1.17 (unch), CMCM: 19.17 (-1.39), IBIO: 1.17 (-0.06), DF: 16.09 (-0.31)

Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST

JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.73 (-0.12)

Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.73 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovation Drives New Asia-Pacific Opportunities

A Glimpse Into The Future: Asia-Pacific's Tech Landscape There's a unique transformation bubbling across the Asia-Pacific scene, with young minds pushing the envelope on technology and innovation. Take Nathapol's team from Thailand, for example. They're merging bionic tech with drones for disaster relief—bold, ambitious, and nearly clinching glory at the Lancang-Mekong...

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

HashKey and ONERWAY Pave New Routes for Digital Payments

New World of On-Chain Payments The landscape of on-chain payments is shifting like sands in a desert storm, but this time HashKey's Settlement Protocol (HSP) ties up with ONERWAY, giving a new direction. These players are looking to redefine how merchants transact with digital currency, tying up loose ends with fiat systems. Strategic Partnership: What’s At Stake? When...

Better's 90-Day Plan: Growth Amidst Governance Gamble

Unpacking the Ambitious 90-Day Plan When you hear Vishal Garg's name next to a 90-day sprint plan, it's not your everyday boardroom shuffle—you know there's grit behind the screen. Better Home & Finance (BETR) is angling for a massive turnaround with its latest rollout, but whether it's all sizzle and no steak is what we're here to figure out. Financial Metrics and...

Innovative Lighting Idea Brightens Indoor Lives

Shedding Light on SUN ORB's Indoor Revolution Sometimes, the best ideas come from simple needs, like wanting a bit of sunshine in your life. That's the deal with this SUN ORB concept—an invention dreamed up by a chap from Oklahoma who's spent too much time away from the natural light outside. We're talking about a wellness-oriented lighting idea that has big ambitions...

Alcatraz AI: A Silent Titan in Data Center Security

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...

Nonprofit Option Rises for Specialty Physicians

Reimaging Choices for Specialty Physicians In the whirlwind of healthcare, specialty physicians often find themselves between a rock and a hard place. The traditional paths are either hug a major health system or auction off to private equity, each option chaining them to systems more interested in the balance sheet than in patient care. But now, a third door opens. One...

Beverly Hills MD's Dermal Cream Wins Key Beauty Award

A Surprise Win in the Beauty World Who doesn't love an underdog story, right? Beverly Hills MD has slid into the limelight with their Dermal Repair Complex snagging the award for 'Beauty Product of the Year.' Talk about sending shockwaves through the beauty industry! Now, these guys might not be a household name yet, but you better believe they've got everyone's attention...

Exploring Before and After School Care Dynamics in PA

Navigating the World of Before and After School Care The dad juggling a morning coffee and a laptop at a crowded diner—he’s not just browsing social media; he's flipping through options for his kid’s care. In Harrisburg, PA, before and after school care isn't just babysitting, it’s a lifeline for working parents balancing the chaos of modern schedules. Timothy R....

Hamamatsu & AIxMed to Automate Cytology Workflows

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...